- Home
- SBFM vs QLGN Comparison
SBFM vs QLGN Comparison
Compare SBFM & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- QLGN
- Stock Information
- Founded
- SBFM 2006
- QLGN 1996
- Country
- SBFM United States
- QLGN United States
- Employees
- SBFM N/A
- QLGN N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- QLGN Health Care
- Exchange
- SBFM Nasdaq
- QLGN Nasdaq
- Market Cap
- SBFM 6.7M
- QLGN 5.8M
- IPO Year
- SBFM N/A
- QLGN N/A
- Fundamental
- Price
- SBFM $1.67
- QLGN $2.88
- Analyst Decision
- SBFM Strong Buy
- QLGN
- Analyst Count
- SBFM 1
- QLGN 0
- Target Price
- SBFM $7.00
- QLGN N/A
- AVG Volume (30 Days)
- SBFM 2.2M
- QLGN 3.4M
- Earning Date
- SBFM 11-12-2025
- QLGN 11-14-2025
- Dividend Yield
- SBFM N/A
- QLGN N/A
- EPS Growth
- SBFM N/A
- QLGN N/A
- EPS
- SBFM N/A
- QLGN N/A
- Revenue
- SBFM $36,341,741.00
- QLGN N/A
- Revenue This Year
- SBFM $21.12
- QLGN N/A
- Revenue Next Year
- SBFM $44.89
- QLGN N/A
- P/E Ratio
- SBFM N/A
- QLGN N/A
- Revenue Growth
- SBFM 19.22
- QLGN N/A
- 52 Week Low
- SBFM $1.17
- QLGN $1.61
- 52 Week High
- SBFM $3.90
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- SBFM 45.56
- QLGN 39.89
- Support Level
- SBFM $1.81
- QLGN $2.66
- Resistance Level
- SBFM $2.13
- QLGN $3.36
- Average True Range (ATR)
- SBFM 0.16
- QLGN 0.54
- MACD
- SBFM -0.04
- QLGN -0.15
- Stochastic Oscillator
- SBFM 7.32
- QLGN 6.04
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.